Format

Send to

Choose Destination
Antimicrob Agents Chemother. 2000 Mar;44(3):688-92.

A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates.

Author information

1
Yale University, New Haven, Connecticut, USA. marie.landry@yale.edu

Abstract

Twelve laboratories collaborated in formulating and testing a standardized plaque reduction assay for cytomegalovirus (CMV) cell-associated clinical isolates. Four characterized and plaque-purified CMV strains, as well as six coded clinical isolates obtained after antiviral therapy, were distributed and tested. Good agreement was obtained for four of the clinical isolates, but a broad distribution of results was obtained for two isolates. Analysis of these results indicates the problems associated with clinical isolates, including the large genetic variability and the highly cell-associated phenotype. This collaborative effort, by addressing these problems, represents a significant step toward the development of a standardized assay.

PMID:
10681339
PMCID:
PMC89747
DOI:
10.1128/aac.44.3.688-692.2000
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center